Investor Overview

Corporate Profile
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases.
Featured Reports
There are currently no items available.
Recent Newsmore >
DateTitle
12/08/16Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Topline results from CIMPASI-1, the second of three Phase 3 trials in psoriasis clinical development program Findings confirm CIMZIA results observed in earlier CIMPASI-2 trial Results from third and final Phase 3 trial expected 1Q17 BRUSSELS, Belgium and MENLO PARK, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-1, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the effica... 
11/09/16Dermira to Present at Stifel 2016 Healthcare Conference
MENLO PARK, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Stifel 2016 Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:00 a.m. ET (8:00 a.m. PT) on Wednesday, November 16, 2016, in... 
11/07/16Dermira Reports Third Quarter 2016 Financial Results and Provides Corporate Update
- Topline results for the first of three Phase 3 trials for CIMZIA® reported - DRM04 Phase 3 and DRM01 Phase 2b data presented at dermatology conferences - Acquired option to license rights to early-stage programs from Takeda - Licensed DRM04 for hyperhidrosis to Maruho in Japan MENLO PARK, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to impr... 
10/21/16Dermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for Dermatologists
MENLO PARK, Calif., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, presented data from its DRM01 Phase 2b clinical trial at the 35th Anniversary Fall Clinical Dermatology Conference in Las Vegas. Positive topline results from the DRM01 Phase 2b dose-ranging clinical trial were previously reporte... 
Stock Quotemore >
DERM (Common Stock)
Exchange :NASDAQ GS (US Dollar)
Price :$29.88
Change (%) : Stock is Up 0.02 (0.07%)
Volume :228,697
Data as of 12/08/16 4:00 p.m. ET
Minimum 20 minutes delay
Eventsmore >
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Dermira, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Minimum 20 minutes delayed